| Literature DB >> 31429747 |
Henry Kwang1, Eric Mou2, Ilana Richman3, Andre Kumar4, Caroline Berube2, Rajani Kaimal5, Neera Ahuja4, Stephanie Harman6, Tyler Johnson7, Neil Shah8, Ronald Witteles9, Robert Harrington9, Lisa Shieh10, Jason Hom11.
Abstract
BACKGROUND: Thrombophilia testing is frequently ordered in the inpatient setting despite its limited impact on clinical decision-making and unreliable results in the setting of acute thrombosis or ongoing anticoagulation. We sought to determine the effect of an educational intervention in reducing inappropriate thrombophilia testing for hospitalized patients.Entities:
Keywords: Education; High value care; Inpatient; Thrombophilia
Mesh:
Year: 2019 PMID: 31429747 PMCID: PMC6701078 DOI: 10.1186/s12911-019-0889-6
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1Duration and distribution of each group and interval
Timing and context used to determine appropriateness of testing
| Assay | Acute Thrombosis | UFH | LMWH | Warfarin | DOAC | Within 2w of stopping VKA |
|---|---|---|---|---|---|---|
| Factor V Leiden | √ | √ | √ | √ | √ | |
| Prothrombin gene mutation | √ | √ | √ | √ | √ | |
| Protein C | ? | ? | ? | X | X | X |
| Protein S | ? | ? | ? | X | X | X |
| Antithrombin III | X | X | X | ? | X | |
| Lupus anticoagulant | √ | X | X | ? | Xa | |
| dRVVT | √ | √ | √ | ? | X | |
| Beta-2 glycoprotein 1 Ab | √ | √ | √ | √ | √ | |
| Anti-cardiolipin Ab | √ | √ | √ | √ | √ | |
| JAK2 mutation | √ | √ | √ | √ | √ |
a False Positive
Criteria Used to Determine Appropriateness of Test Ordering
| Inappropriate Ordering | |
| Patient characteristics | |
| Provoked VTE occurring in the setting of major transient risk factor | |
| Women with pregnancy-related VTE | |
| Patients with advanced liver disease and abnormal function | |
| Ordering factor V Leiden or prothrombin gene mutation in patients who have had a liver transplant (no correlation between patient’s DNA and factor status produced by the new liver) | |
| Testing for the MTHFR polymorphism (obsolete test, does not correlate with risk of VTE) | |
| Timing issues | |
| Ordering antithrombin III, protein C or S level during the first 3 months of anticoagulant therapy | |
| Ordering protein C or S levels during warfarin therapy, or within 2 weeks of stopping warfarin | |
| Ordering lupus anticoagulant, antithrombin III, protein C or S levels in patients on novel oral anticoagulants | |
| Duplicate ordering of heritable thrombophilias: factor V Leiden, prothrombin gene mutation, JAK2 V167F mutation). | |
| Ordering of heritable thrombophilia workups (FV Leiden, Prothrombin gene mutation, and protein C/S levels) in the inpatient setting, if fails to impact clinical management decisions. | |
| Appropriate Ordering | |
| Patients with unprovoked VTE in whom test results may impact duration or choice of anticoagulant (e.g. positive antiphospholipid antibody screening) | |
| Patients with VTE and multiple family members with history of VTE (higher risk of thrombophilia such as AT3 deficiency) | |
| Thrombosis at unusual sites (e.g. splanchnic, Budd-Chiari, renal, or cerebral venous thrombosis) | |
| Recurrent provoked VTE | |
| Screen for antiphospholipid antibody in the setting of recurrent pregnancy loss (we can define further) | |
| Unexplained arterial thromboses | |
| Ordering antiphospholipid antibody testing in the setting of arterial thrombosis (e.g. peripheral arterial events, CVA) | |
| Unclear Ordering | |
| Female patients who develop VTE on hormonal therapy | |
| Patients with upper extremity DVT | |
| Testing ordered at the patient’s request | |
| VTE with minor risk factor (e.g. travel-related or flight < 6-8 h, minor surgery, prolonged sitting, etc.) | |
| VTE in young patients with stroke and PFO |
Frequency and percent of inappropriate thrombophilia tests among interventional groups - pre and post intervention
| Group | Pre-Intervention | Post-Intervention | |
|---|---|---|---|
| Early Intervention | 2/5 (40.0%) | 13/53 (24.5%) | 0.60a |
| Late Intervention | 18/46 (39.1%) | 10/43 (23.3%) | 0.11 |
| Combined Intervention | 20/51 (39.2%) | 23/96 (24.0%) | 0.053 |
P values from Chi square test except where indicated
a Fisher Exact test
Estimated impact of intervention by intervention cohort and comparison groupa
| Intervention group | Comparison | ||
|---|---|---|---|
| Within intervention | Contemporary controls | Historical controls | |
| Odds Ratio (95% CI); | Odds Ratio (95% CI); | Odds Ratio (95% CI); | |
| Overall | 0.47 (0.14, 1.61); 0.23 | 0.46 (0.12, 1.71); 0.25 | 0.42 (0.09, 2.06); 0.29 |
| Early intervention | 0.49 (0.08, 2.98); 0.44 | 0.46 (0.09, 2.40); 0.35 | 0.47 (0.08, 2.91); 0.42 |
| Late intervention | 0.47 (0.11, 2.04); 0.32 | 0.43 (0.10, 1.77); 0.24 | 0.37 (0.06, 2.35); 0.29 |
CI Confidence Interval. p = Wald p-value
a All models include clustering for patient and provider
Fig. 2Percentage of inappropriate tests in each time interval
Tests and Confidence Intervala per 1000 patients admitted
| Pre-Intervention | Post-Intervention | ||
|---|---|---|---|
| Early Interventiona | |||
| Inappropriate tests | 3.68 (0–8.76) | 3.13 (1.43–4.83) | 0.832 |
| Appropriate tests | 5.51 (0–11.74) | 9.63 (6.63–12.61) | 0.343 |
| Late intervention | |||
| Inappropriate tests | 8.47 (4.57–12.36) | 3.89 (1.48–6.30) | 0.043 |
| Appropriate tests | 13.17 (8.32–18.02) | 12.84 (8.49–17.19) | 0.92 |
a Lower confidence limit restricted to 0